Aeterna Zentaris (AEZS) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results
May 8, 2017 4:30 PM EDTAll amounts are in US Dollars
Highlights
Company reported on May 1 that ZoptEC Phase 3 clinical study of ZoptrexTM (zoptarelin doxorubicin) did not achieve its primary endpoint; further development of product to be discontinued
Company announced on March 30 that, following its meeting with the FDA it intends to file a new drug application seeking approval of MacrilenTM (macimorelin) for the evaluation of growth hormone deficiency in adults
Adequate liquidity and resources to fund operations through expected Macrilen approval
$17.8 million of unrestricted... More